Table 3.
Prevalence of dyslipidemia and hyperglycemia in HIV-infected patients according to stavudine- and zidovudine-containing regimens.
| Stavudine | Zidovudine | Total | ||
|---|---|---|---|---|
| Lipid abnormalities | N = 208 | N = 215 | N = 423 | P value |
| N (%) | N (%) | N (%) | ||
| Total cholesterol | ||||
| Borderline | 58 (27.9) | 48 (22.3) | 106 (25.1) | 0.018 |
| High | 35 (16.8) | 24 (11.2) | 59 (14.0) | |
| LDL-cholesterol | ||||
| Borderline | 29 (13.9) | 17 (7.9) | 46 (10.9) | 0.013 |
| High | 22 (10.6) | 15 (7.0) | 37 (44.6) | |
| Triglycerides | ||||
| Borderline | 40 (19.2) | 31 (14.4) | 71 (16.8) | 0.025 |
| High | 19 (9.1) | 10 (4.7) | 29 (6.9) | |
| HDL-cholesterol | ||||
| Borderline | 147 (70.7) | 87 (40.5) | 234 (55.3) | <0.001 |
| Low | 12 (5.8) | 7 (3.3) | 19 (4.5) | |
| Dyslipidemia | ||||
| Borderline | 190 (91.4) | 155 (72.1) | 345 (81.6) | <0.001 |
| Overt | 46 (22.1) | 34 (15.8) | 80 (18.9) | |
| Hyperglycemia | ||||
| Borderline | 23 (11.1) | 38 (17.7) | 61 (14.4) | |
| Overt | 6 (2.9) | 11 (5.1) | 17 (4.0) |
TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein.